Full text is available at the source.
Ganoderma lucidum polysaccharide inhibits HSC activation and liver fibrosis via targeting inflammation, apoptosis, cell cycle, and ECM-receptor interaction mediated by TGF-β/Smad signaling
Ganoderma lucidum polysaccharide may reduce liver scarring by targeting inflammation, cell death, cell growth, and tissue structure through TGF-β/Smad signaling
AI simplified
Abstract
GLP (150 and 300 mg/kg) significantly inhibited hepatic fibrogenesis and inflammation in CCl-treated mice.
- Ganoderma lucidum polysaccharide (GLP) may exert anti-fibrotic effects via the TLR4/NF-κB/MyD88 signaling pathway.
- GLP significantly reduced collagen I and alpha-smooth muscle actin (a-SMA) expressions, indicating inhibited hepatic stellate cell activation.
- RNA-sequencing identified key pathways suppressed by GLP, including inflammation, apoptosis, and cell cycle regulation.
- GLP showed a dual effect on apoptosis, inhibiting it in vivo while promoting it in vitro.
- GLP treatment resulted in the attenuation of ECM-receptor interaction-related molecules, particularly integrins ITGA6 and ITGA8.
- Inhibition of TGF-β/Smad signaling was observed, with reduced phosphorylations of Smad2 and Smad3 and increased Smad7 expression in HSC-T6 cells.
AI simplified